Scott Baron, MD
Interventional Cardiology · Carmichael, CANPI 1215038930
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $184,823 of the $230,681 with a category attached, or 80.1%. 42 manufacturers reported payments, led by Merck at 55.6% of the total. Reporting peaked in 2023 at $73,776 and has fallen 83.9% since, to $11,865 in 2025. Among interventional cardiology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 677 payments — averaging $340.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$128K
- Amgen$40K
- Novartis$14K
- Pfizer$13K
- Lexicon Pharmaceuticals, Inc.$9K
- E.r. Squibb & Sons, L.L.C.$6K
- plus $21K from 36 others
Across 17 payments — averaging $6896.95 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Akcea Therapeutics, Inc.$80K
- Novartis$37K
What the payments were for
- Consulting fees$1,7681%
- Speaking & faculty fees$184,82380%
- Travel & lodging$30,15613%
- Food & beverage$13,8356%
- Education$980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VERQUVO$198,409
- Repatha$38,626
- ELIQUIS$18,058
- ENTRESTO$13,324
- Inpefa$8,811
- Amplatzer Cardiac Plug$3,759
- FARXIGA$3,750
- AMPLATZER Occluders$1,907
- MULTAQ$1,768
- CoreValve Evolut$1,447
- Assure WCD$167
- IGT Devices Und$148
- GORE CARDIOFORM Septal Occluder$141
- COREVALVE EVOLUT R$137
- Ozempic$114
- Barostim Neo System$109
- Impella$100
- FLOWTRIEVER CATHETER, S$100
- CT THROMBECTOMY SYSTEM KIT$100
How this compares
$230,681 in reported general payments places this provider in the 95th percentile of 585 interventional cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 388 | $471,383 |
| EntrestoSacubitril/Valsartan | 318 | $331,572 |
| VyndamaxTafamidis | 12 | $264,144 |
| FarxigaDapagliflozin Propanediol | 235 | $222,756 |
| Repatha SureclickEvolocumab | 189 | $198,492 |
| JardianceEmpagliflozin | 224 | $195,335 |
| XareltoRivaroxaban | 83 | $92,308 |
| Repatha SyringeEvolocumab | 72 | $57,718 |
| MultaqDronedarone Hcl | 40 | $54,036 |
| Praluent PenAlirocumab | 47 | $46,053 |
| VascepaIcosapent Ethyl | 76 | $46,051 |
| BrilintaTicagrelor | 48 | $30,611 |
| RybelsusSemaglutide | 16 | $29,932 |
| Icosapent Ethyl | 55 | $15,612 |
| Bosentan | 12 | $14,934 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Vyndamax | $12,760 | $735,528400 claims |
| NovartisEntresto | $13,788 | $331,572318 claims |
| AstraZenecaFarxiga, Brilinta | $4,122 | $253,367283 claims |
| Boehringer IngelheimJardiance | $249 | $195,335224 claims |
| Johnson & JohnsonXarelto | $510 | $92,30883 claims |
| Sanofi-aventis U.S. LLCMultaq | $2,195 | $54,03640 claims |
| Novo NordiskRybelsus | $278 | $29,93216 claims |
| Arbor Pharmaceuticals, Inc.Edarbi, Edarbyclor | $37 | $17,65125 claims |
| Actelion Pharmaceuticals US, Inc.Bosentan | $272 | $14,93412 claims |
| Esperion Therapeutics, Inc.Nexlizet | $88 | $14,36216 claims |
| Lexicon Pharmaceuticals, Inc.Inpefa | $9,174 | $7,10612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 585 interventional cardiology providers in California.
Other interventional cardiology in Carmichael
- Matthew Pricela Jolla$2.3M
- Frederick St GoarMountain View$2.2M
- Saibal KarThousand Oaks$1.1M
- Rahul SharmaStanford$1M
- Puneet KhannaRancho Mirage$1M
- Dennis SheehanRedwood City$900K
- Suhail DohadBeverly Hills$802K
- Curtiss Stinisla Jolla$759K
- Christian SpiesBurlingame$719K
- Evan ZahnLos Angeles$632K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.